Pharma ETFs In Focus Post Q1 Earnings

Image: Bigstock

Healthcare Q1 results seem robust given that total earnings for the quarter as a whole are expected to be up 24.6% on revenue growth of 10%.

Many industry bigwigs reported mixed results with some beating on earnings or revenues or both, while a few missed the estimates on both fronts. Many of them lifted the outlook for the full year. Let’s delve deeper into a few of them:

Earnings in Focus

Johnson and Johnson

The world's biggest healthcare products’ maker continued its long streak of earnings beat and outpaced revenue estimates. Earnings per share came in at $2.59, beating the Zacks Consensus Estimate of $2.31 and improving 12.6% from the year-ago quarter. Revenues grew 7.9% year over year to $22.3 billion and edged past the Zacks Consensus Estimate of $21.82 billion. For 2021, Johnson & Johnson narrowed its revenue range from $90.5-$91.7 billion to $90.6-$91.6 billion, indicating a year-over-year increase of 9.7-10.9%. The earnings per share guidance range has been revised from $9.40-$9.60 to $9.42-$9.57, representing year-over-year growth of 17.3-19.2%.

Pfizer

Pfizer also topped on both fronts. Earnings per share of 93 cents were well above the Zacks Consensus Estimate of 79 cents. Revenues of $14.58 billion edged past the consensus mark of $13.49 billion. On a year-over-year basis, earnings and revenues increased 47% and 45%, respectively. The U.S. drug giant raised its revenue guidance to $70.5-$72.5 billion from $59.4-$61.4 billion, indicating year-over-year growth of 71%, and earnings guidance to $3.55-$3.65 from $3.10-$3.20 per share, indicating year-over-year growth of 59%, for 2021.

Merck

Merck reported weaker-than-expected results. Earnings per share of $1.40 missed the Zacks Consensus Estimate of $1.63 and declined 7% from the year-ago quarter. Revenues were flat year over year at $12.08 billion and below the consensus mark of $12.84 billion. For 2021, Merck maintained its revenue guidance in the range of $51.8-$53.8 billion, which indicates year-over year growth of 8-12%, while adjusted earnings are expected in the range of $6.48-$6.68 per share.

1 2 3
View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.